Combination of Antiviral Drugs to Inhibit SARS-CoV-2 Polymerase and Exonuclease as Potential COVID-19 Therapeutics
X. Wang, C. Q. Sacramento, S. Jockusch, O. A. Chaves, C. Tao, N. Fintelman-Rodrigues, M. Chien, J. R. Temerozo, X. Li, S. Kumar, W. Xie, D. J. Patel, C. Meyer, A. Garzia, T. Tuschl, , J. Ju
This study identifies HCV NS5A inhibitors as SARS-CoV-2 exonuclease inhibitors and shows synergy in combination with polymerase inhibitors to enhance antiviral efficacy.
bioRxiv · Jul 21, 2021 · PreprintPharmacology & Toxicology